Venatorx Pharmaceuticals Announces Positive Results for Phase 3 Clinical Trial (CERTAIN-1) of Cefepime-Taniborbactam for Treatment of cUTI
Venatorx Pharmaceuticals today announced positive results from its pivotal Phase 3 study evaluating cefepime-taniborbactam, an investigational new drug, as a potential treatment for adult patients with complicated urinary tract infections (cUTI), including acute pyelonephritis.
Cefepime, a fourth-generation cephalosporin, is a widely used beta-lactam (BL) antibiotic with more than two decades of proven safety and clinical utility against susceptible gram-negative and gram-positive bacteria. Taniborbactam is a beta-lactamase inhibitor (BLI) that, in combination with cefepime, may offer a potential treatment option for patients with serious bacterial infections caused by difficult-to-treat drug resistant gram-negative bacteria, most notably carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA). Many of these organisms are also multidrug-resistant (MDR), further limiting treatment options. Cefepime-taniborbactam has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation by the U.S. Food and Drug Administration (FDA).
CERTAIN-1 (Cefepime Rescue with Taniborbactam in cUTI) was a global, randomized, double-blind, active-controlled non-inferiority Phase 3 study evaluating the efficacy, safety, and tolerability of cefepime-taniborbactam compared to meropenem in adults with cUTI, including acute pyelonephritis. The trial enrolled 661 adult patients who were randomized 2:1 to receive cefepime-taniborbactam 2.5g q8h or meropenem 1g q8h for 7 days (up to 14 days for patients with bacteremia). The primary efficacy endpoint evaluated the composite clinical and microbiologic response (i.e., bacterial eradication) at the Test of Cure (TOC) visit (Day 19-23) in the microbiological intent-to-treat (microITT) population as specified by FDA and European Medicines Agency guidance.
Cefepime-taniborbactam met the primary efficacy endpoint of statistical noninferiority (NI) to meropenem in the microITT population at TOC with composite microbiologic and clinical success occurring in 70.0% of cefepime-taniborbactam treated patients and 58.0% of meropenem treated patients (treatment difference 11.9; 95% confidence interval (CI), 2.4, 21.6). A prespecified superiority test following confirmation of NI demonstrated the statistical superiority of cefepime-taniborbactam for the composite endpoint at TOC. The superiority of cefepime-taniborbactam was sustained for the composite microbiologic and clinical response at the Late-Follow-Up (Day 28-35) visit.
Rates of treatment-emergent adverse events (TEAEs) were 35.5% for cefepime-taniborbactam and 29.0% for meropenem. Serious TEAEs occurred in 2.0% and 1.8% of cefepime-taniborbactam and meropenem treated patients, respectively. Treatment discontinuations due to TEAEs occurred in 3.0% of cefepime-taniborbactam patients and 0.9% of meropenem treated patients. There was one death in the cefepime-taniborbactam treatment group, which was unrelated to study treatment as assessed by the investigator.
Complete CERTAIN-1 study results will be presented at an upcoming scientific meeting.
“These data demonstrate that cefepime-taniborbactam may represent a significant improvement over the standard of care and could support global health efforts to combat antibiotic-resistant infections,” said Christopher J. Burns, Ph.D., President and CEO of Venatorx. “Cefepime-taniborbactam, if approved by the FDA, may offer a new treatment option for patients with infections caused by highly resistant bacteria, even those resistant to widely used carbapenem antibiotics. We want to thank the patients who enrolled in the trial, the clinical investigators who participated in the study, as well as our employees and partners for their steadfast support and determination to bring a lifesaving medicine to patients around the world. We plan to submit a New Drug Application with the FDA for cefepime-taniborbactam for the treatment of cUTI in adult patients later this year.”
About Gram-Negative Infections and Antimicrobial Resistance (AMR)
According to the U.S. Centers for Disease Control and Prevention (CDC), rates of resistance for certain gram-negative bacteria have increased significantly in the U.S. and are common causes of cUTI, acute pyelonephritis, and bacteremia. In a recent report on AMR, the CDC cited that there are more than 2.8 million AMR infections annually in the U.S. which are directly related to more than 35,000 deaths.[i] Between 2014 and 2019, an analysis of U.S. UTI patients determined that 4.4% of cases were carbapenem resistant (CR) and 24.5% of U.S. UTI patients were bacteremic with 1.7% of cases caused by a CR pathogen. Patients with CR infections had a significantly longer hospital length of stay (LOS), were less likely to be discharged home, had a higher readmission rate, and had greater LOS-associated charges than patients with carbapenem-susceptible infections. Additionally, bacteremic (urosepsis) CR patients had a significantly higher rate of mortality than those with carbapenem susceptible bacteremia.[ii]
If AMR infections continue on this trajectory, it is estimated that there will be 10 million deaths per year by 2050—a number that surpasses the projected number of deaths (8.2 million) caused by cancer—and the cumulative cost to the global economy could be as high as US$100 trillion.[iii] In the U.S., estimates have reached as high as US$20 billion in excess direct healthcare costs, with an additional US$35 billion associated with lost productivity.[iv] By 2050, the world is at risk of losing up to 3.8% of its annual gross domestic product with an annual shortfall of up to US$3.4 trillion by 2030, a figure on par with losses attributable to the 2008 global financial crisis.[v] For those patients who do not respond to current treatment, new antibiotic therapies are needed to combat AMR.
About Complicated Urinary Tract Infections (cUTIs)
cUTIs, which include acute pyelonephritis, are defined as urinary tract infections ascending from the bladder accompanied by local and systemic signs and symptoms, including fever, chills, malaise, flank pain, back pain, and/or costovertebral angle pain or tenderness, that usually occur in the presence of a functional or anatomical abnormality of the urinary tract or in the presence of catheterization. Bacteremia can arise secondary to acute systemic infections like cUTI and can result in substantial morbidity and mortality.[i] Annually, it is estimated that more than 3 million cUTI patients would be diagnosed and require antibiotic therapy leading to over $6 billion in annualized 30-day costs.[vi]
Funding Partners and Collaborators for Cefepime-Taniborbactam
Development of cefepime-taniborbactam began with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract number HHSN272201300019C, and Wellcome Trust under Award No. 360G-Wellcome-101999/Z/13/Z, and continues with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under contract number HHSO100201900007C.
In September 2018, Venatorx entered into an exclusive license agreement with Everest Medicines to support the development, registration and commercialization of cefepime-taniborbactam in Greater China, South Korea, and select countries in Southeast Asia. Everest will be solely responsible for the commercialization of cefepime-taniborbactam in its territory and Venatorx will be eligible to receive royalties on net sales.
In April 2020, Venatorx and GARDP announced a collaboration to accelerate the development of, and access to, cefepime-taniborbactam for adult and pediatric populations. Venatorx has granted GARDP exclusive rights to distribute and sub-distribute cefepime-taniborbactam, once it is approved for clinical use, in low- and lower-middle-income countries.
About Venatorx Pharmaceuticals, Inc.
Venatorx is a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections. Venatorx’s lead program, cefepime-taniborbactam, is a clinical-stage antibiotic that completed a Phase 3 study in adults with complicated urinary tract infections. Based on positive results from the CERTAIN-1 Phase 3 clinical trial, the Company expects to submit a New Drug Application with the U.S. Food and Drug Administration for cefepime-taniborbactam in the fourth quarter 2022. Venatorx also has an oral antibacterial clinical-stage program, ceftibuten/VNRX-7145, that is in Phase 1. For more information about Venatorx and its anti-infectives portfolio, please visit www.venatorx.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical development of Venatorx Pharmaceuticals’ product candidates.
[i] Antibiotic Resistance Threats in the United States 2019, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.
[ii] Shields et al. Burden of illness in U.S. hospitals due to carbapenem-resistant gram-negative urinary tract infections in patients with or without bacteremia. BMC Infectious Diseases (2021) 21:572.
[iii] O’Neill, J. ‘Tackling Drug-Resistant Infections Globally: Final Report and Recommendations’. Review on Antimicrobial Resistance. May 2016.
[iv] Antibiotic Resistance Threats in the United States 2013, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.
[v] World Bank. Final Report Drug Resistant Infections: A Threat to Our Economic Future. Mar 2017.
[vi] Carreno et al. Longitudinal, nationwide, cohort study to assess incidence, outcomes, and costs associated with complicated urinary tract infection. Open Forum Infectious Diseases.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005341/en/
Vice President, Communications
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GMS ranked as a Tier 1 SMS Firewall Vendor by ROCCO Research30.5.2023 10:00:00 CEST | Press release
Global Message Services (GMS), a trusted communications service provider for Enterprises and Mobile Operators worldwide, has been rated as a Tier 1 SMS Firewall Vendor in the ROCCO SMS Firewall Benchmarking Survey, for a second year running. This year, GMS topped the Tier 1 leaderboard featuring six vendors, attaining an overall rating of 4.53 out of 5. It received top scores for a range of KPIs, including reliability, customer service, technical expertise, transparency, and industry awareness. It also achieved a net promoter score of 93 - the best among all the vendors who participated. For the 2023 edition of this annual survey, ROCCO Research collected feedback from 239 MNOs spread across 136 countries. Some 46% of vendors who took part in the survey reported that they have experienced an increase in SMS attacks. The survey also confirmed that despite AI advances, the human element remains essential for SMS firewall protection. Charles Upchurch, CEO, GMS said: "Even as firewall mana
Regnology Enters into Exclusive Talks to Acquire Invoke30.5.2023 08:19:00 CEST | Press release
Regnology, a leading software provider with a focus on regulatory reporting solutions, announces today it expects to sign a definitive agreement to acquire Invoke, a French-based provider of financial, regulatory, and tax reporting solutions for supervisory authorities, and reporting entities. On completion of the agreement, the deal would mark the fifth acquisition in less than a year for Regnology. With 160+ full-time employees, Invoke serves over 1,800 regulated entities and supervisory authorities throughout Europe with its XBRL-based banking, insurance, and tax reporting solutions. Invoke’s corporate tax solution will complement Regnology’s financial tax reporting solution and open a new growth area for the company. Rob Mackay, CEO of Regnology, comments: “The round of recent deals we have undertaken, culminating with today’s announcement, sets Regnology on an accelerated path for growth internationally. Invoke’s advanced solutions would complement our technology stack while its t
William O'Neil + Company Announces the Passing of William J. O'Neil30.5.2023 05:21:00 CEST | Press release
William J. O'Neil, "Bill," a highly accomplished figure in the world of stock speculation, entrepreneurship, authorship, and philanthropy has passed away at the age of 90. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230529005167/en/ William J. O'Neil (Photo: Business Wire) Bill exemplified the American spirit and firmly believed that through hard work, anyone could attain prosperity. His approach to success was characterized by his willingness to challenge conventional wisdom, carefully analyze the data, and follow it wherever it led him, on his own terms. With humble beginnings, he became the youngest person to purchase a seat on the New York Stock Exchange at 30 years old. He wrote several best-selling books sharing the investment methodologies he built his businesses upon and devoted much of his life to extending a path toward financial freedom for all. He was a vocal proponent of a free enterprise system and its contr
Huawei ICT Competition 2022-2023 Global Final Held in Shenzhen — 146 Teams from 36 Countries and Regions Win Awards30.5.2023 04:54:00 CEST | Press release
On May 27, 2023, the Huawei ICT Competition 2022-2023 Global Final concluded in Shenzhen, drawing to a close the seventh installment of this competition. The first to be held in person since 2019, the event’s culmination was a competition between finalists in 146 teams from 36 countries. Before the Final, more than 120,000 students from more than 2000 universities in 74 countries and regions around the world took part in the ICT Competition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230529005085/en/ Huawei ICT Competition 2022–2023 Global Final Closing and Awarding Ceremony (Photo: Huawei) Teams from Shenzhen Polytechnic, Guilin University of Electronic Technology, Guangzhou College of Commerce, Yangtze Normal University, and Hunan Industry Polytechnic won the Network Track Grand Prize. Teams from Guilin University of Electronic Technology, Shenzhen Polytechnic, and Nanning College for Vocational Technology won the Clou
Tourists from Four Asian Countries and Regions Can Now Pay in Thailand with Mobile Wallets30.5.2023 04:21:00 CEST | Press release
Ant Group, the operator of Alipay+, the global cross-border digital payments and marketing solution today announced that a total of four mobile wallets are now accepted in Thailand. These include AlipayHK (Hong Kong SAR), Kakao Pay (South Korea), Touch ‘n Go eWallet (Malaysia) and Alipay (Chinese mainland), which has been accepted by Thai merchants since 2015. Enabled through Alipay+, the latest development and the addition of three more mobile wallets will expand the seamless digital travel experience for more Asian tourists visiting Thailand, in the midst of a rapid rebound in the local tourism industry. Ant Group also unveiled new collaborations with the Tourism Authority of Thailand (“TAT”), to promote the Amazing Thailand campaign and to stimulate travel in Thailand. In addition to facilitating purchases and transactions made by mobile wallets familiar to tourists, Ant Group will also provide digital solutions to local businesses in areas such as digitalisation of service operatio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom